GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

enVVeno Medical NVNO · USD

Health Care · US listing · 🇺🇸 United States

Compare

6.85

+1.78%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About enVVeno Medical

From its filings with the US Securities and Exchange Commission

SEC filings

enVVeno Medical is based in Irvine, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker NVNO. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2019, it reported revenue of $31,243.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
31 May 2018
Employees
30
Website
envveno.com ↗
Head office
70 DOPPLER, IRVINE, CA, 92618
Incorporated in
DE
Classification
Surgical & Medical Instruments & Apparatus
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. Robert BermanChief Executive Officer, Director, since 2018$1.2m
  • Ms. Jennifer BrightChief Financial Officer
  • Dr. Hamed AlaviSenior Vice President, Chief Technology Officer$521,895
  • Dr. Marc GlickmanSenior Vice President, Chief Medical Officer, since 2016$626,573
  • Dr. Francis DuhayIndependent Director$70,000
  • Mr. Robert GrayIndependent Director$77,500
  • Mr. Matthew JenusaitisIndependent Director$75,000
  • Dr. Sanjay ShrivastavaIndependent Director$75,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Developing bioprosthetic solutions for cardiovascular disease treatment
  • VenoValve surgical replacement venous valve for severe CVI patients
  • SAVVE clinical trial evaluating VenoValve in the US market

Weaknesses

  • 30 full-time employees in development stage company
  • IPO listing date 31 May 2018 for a development stage firm
  • Limited product portfolio with only VenoValve in development

Opportunities

  • Expansion of VenoValve clinical trial to additional US medical centers
  • Growing market for venous disease treatment solutions in the US
  • Potential FDA approval for VenoValve as standard treatment option

Threats

  • Competition from established medical device companies in cardiovascular sector
  • Regulatory delays in FDA approval process for VenoValve
  • Risk of clinical trial failure in SAVVE trial for VenoValve product

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.